secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001213900-24-068243
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell Q2 product sales up 55% but net loss $1.5M; FDA incomplete letter for Re-Tain
--------------------------------------------------------------------------------

- Product sales $5.5M (+55% YoY); six-month sales $12.7M (+82% YoY).
- Net loss $1.5M ($0.20/sh) in Q2 2024 vs $1.4M loss ($0.18/sh) in Q2 2023.
- Gross margin fell to 22% from 30% due to contamination issues and yield losses.
- FDA issued CMC Technical Section Incomplete Letter for Re-Tain; resubmission hinges on contract manufacturer inspection resolution.
- Backlog $7.9M as of Aug 6 2024, down from $9.4M at Dec 31 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390024068243/0001213900-24-068243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390024068243/ea0211270-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-068243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer